Screening & monitoring · graded by use, two uses
HPV testing for cervical cancer screening
Invasive cervical cancer, HPV-based against cytology-based screening, women aged 20 to 64.
At a glance
This is about testing for HPV, the virus behind most cervical cancer, to find early changes. In four European studies, women screened with an HPV test got invasive cervical cancer less often than women screened with a Pap test. In one large study in rural India, one HPV test cut deaths from cervical cancer by about half. One Pap test or a visual check did not clearly lower deaths there.
- What was measured
- New cases of invasive cervical cancer, found through cancer registries and pathology records, in women screened with an HPV test or with a Pap test.
- How big
- The authors summed up the four trials as 60% to 70% greater protection against invasive cervical cancer with HPV-based screening than with the Pap test. The summary gives a relative figure, not the number of women.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 24192252.
- Who it applies to
- 176,464 women aged 20 to 64 in regular screening programs in Sweden, the Netherlands, England and Italy, followed for a median of 6.5 years. Women under 25 and HPV vaccination were outside what was graded.
- Safety
- A positive HPV test leads to a closer look at the cervix (colposcopy) and sometimes to treatment of changes that would not have grown; the Indian trial reported mild side effects in 0.1% of screened women.
- Compared with
- Screening with the Pap test (a check of cervical cells under the microscope).
- Certainty
- Grade B, resting on: Randomized trials of HPV-based screening against cytology or no screening.
- What would change this grade
- Could rise to A with: A large randomized trial of HPV-based against cytology-based screening with invasive cervical cancer as the prespecified primary outcome, run by a group independent of the four European trials. Who: Women aged 30 to 64 in an organized screening program. Measured: Invasive cervical cancer confirmed by masked histology review, with cervical cancer deaths reported. Length: At least two screening rounds and 10 years of follow-up.
- Cost
- No price recorded yet.
- Sources
- 5 studies cited on this record, listed under Sources.
The B belongs to one of the two uses graded on this record. The other one carries its own letter.
As studied, and the trials
Ronco et al. (Lancet, 2014; PMID 24192252) followed four randomized trials run by separate national groups: invasive cervical cancer was 40% less frequent with HPV-based screening (rate ratio 0.60, 0.40 to 0.89), with no heterogeneity How much the results of the pooled trials differ from each other. High heterogeneity makes a combined estimate less reliable. between trials, and 55% less frequent after the first 2.5 years. The trials' own reports are POBASCAM (Rijkaart et al., Lancet Oncol, 2012; PMID 22177579), NTCC (Ronco et al., Lancet Oncol, 2010; PMID 20089449) and Swedescreen (Naucler et al., N Engl J Med, 2007; PMID 17942872). Replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. on a hard outcome, but as a follow-up rather than the trials' primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight.: B.
As studied, and the trials
Sankaranarayanan et al. (N Engl J Med, 2009; PMID 19339719): 34 cervical cancer deaths with one round of HPV testing against 64 with standard care (hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. 0.52, 0.33 to 0.83); one round of cytology or visual inspection did not significantly reduce deaths. One cluster trial, not repeated: C under Rule 06.
Read the grade that matches your goal. How EBL grades by use →
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →HPV testing for cervical cancer screening, graded on invasive cervical cancer with HPV-based against cytology-based screening: what the randomized trials measured, in whom, and what they did not show.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on invasive cervical cancer with HPV-based against cytology-based screening: four independent European trials, pooled to 40% fewer invasive cancers (PMID 24192252).
WHY NOT Ainvasive cancer was a follow-up outcome, not the trials' primary endpoint, which was precancer. Grade C on cervical cancer deaths with one round of HPV testing against standard care: one cluster trial in India (PMID 19339719), not yet repeated (Rule 06).
WHAT THIS GRADE DOES NOT COVERthe Pap test against no screening, which no repeated-round randomized trial has tested and which a single round did not clearly improve in India (PMID 19339719); HPV vaccination; and women under 25.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Evidence notes: randomized trial, independently replicated
Endpoint graded: Invasive cervical cancer with HPV-based against cytology-based screening (hard)
Last reviewed: October 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
In the four European trials invasive cancer was a follow-up outcome after a primary outcome of precancer (PMID 24192252), and the only trial on cervical cancer deaths is a single cluster trial in India (PMID 19339719). A trial powered for invasive cancer as its primary outcome, confirming the pooled reduction, would meet the bar for A.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for HPV Testing among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of HPV Testing on ClinicalTrials.gov
Dose, form and timing
Measured in the trials: invasive cervical cancer diagnoses in registries, advanced cancer, and deaths from cervical cancer.
Safety
A positive HPV test leads to colposcopy and sometimes to treatment of the cervix for changes that would not have progressed; mild adverse events were reported in 0.1% of screened women in the Indian trial (PMID 19339719).
Cautions documented in human studies. Each caution on this record, sorted by what it rests on.
- A positive test leads to colposcopy and sometimes treatment of changes that would not have progressed, and mild adverse events occurred in 0.1% in the Indian trial. (PMID 19339719)
None recorded.
None recorded.
None recorded.
Does not apply: human harm data are listed above.
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- October 2026. By the EBL editor, Arnold Sandlow, DC.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
Primary evidenceFive papers, each linked to its PubMed record.
Ronco et al. (Lancet, 2014; PMID 24192252): follow-up of four European randomized trials (Swedescreen, POBASCAM, ARTISTIC, NTCC), 176,464 women aged 20 to 64, HPV-based against cytology-based screening; invasive cervical cancer rate ratio 0.60 (0.40 to 0.89) over a median 6.5 years, with no heterogeneity between trials, and 0.45 (0.25 to 0.81) after the first 2.5 years; the trials' own primary endpoint was precancer. Sankaranarayanan et al. (N Engl J Med, 2009; PMID 19339719): 131,746 women aged 30 to 59 in 52 village clusters in India, one round of HPV testing, cytology or visual inspection against standard care; advanced cervical cancer hazard ratio 0.47 and cervical cancer deaths 34 against 64 (0.52, 0.33 to 0.83) with HPV testing; no significant reduction with cytology or visual inspection; mild adverse events in 0.1% of screened women. The trial reports: POBASCAM (Rijkaart et al., Lancet Oncol, 2012; PMID 22177579), NTCC (Ronco et al., Lancet Oncol, 2010; PMID 20089449) and Swedescreen (Naucler et al., N Engl J Med, 2007; PMID 17942872), each with precancer as its primary endpoint.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(HPV[ti] OR papillomavirus[ti]) AND screening[ti] AND randomized controlled trial[pt] AND (invasive[tiab] OR mortality[tiab] OR deaths[tiab])PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since October 2026.
Last run October 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
This page carries a letter. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a page says EBL earns a commission on anything that carries a letter, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →